Literature DB >> 2505184

Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure.

J Kindler1, K U Eckardt, B Ehmer, K Jandeleit, A Kurtz, A Schreiber, P Scigalla, H G Sieberth.   

Abstract

The pharmacokinetic profile of recombinant human erythropoietin (rHuEpo) was studied after a single intravenous dose of 150 U/kg in ten patients with various degrees of renal function: group I, creatinine clearance greater than 80 ml/min, n = 2; group II, creatinine clearance 10-50 ml/min, n = 6; group III, creatinine clearance less than 3 ml/min (patients undergoing haemodialysis) n = 2. Erythropoietin concentrations in serum and urine samples obtained over 48 h were measured by RIA. rHuEpo was cleared from circulation in an exponential fashion, the half-life ranged from 6.5 to 12.7 h (mean 9.03 h) and was not different between the groups. The apparent volume of distribution varied from 0.041 to 0.099 l/kg (mean 0.070 l/kg) this corresponds to 1.5 times the plasma volume and was unrelated to kidney function. Renal clearance (groups I, II) accounted for less than 3% of total body clearance, both parameters were unaffected by decreasing renal function. These results indicate that, in accordance with animal data, the elimination of rHuEpo occurs mainly through non-renal mechanisms.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2505184     DOI: 10.1093/oxfordjournals.ndt.a091888

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  16 in total

Review 1.  Pharmacokinetics of newer drugs in patients with renal impairment (Part I).

Authors:  J P Fillastre; E Singlas
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

2.  An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis.

Authors:  Desmond Padhi; Liyun Ni; Blaire Cooke; Rafael Marino; Graham Jang
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs.

Authors:  David Czock; Frieder Keller; Hanna M Seidling
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

Review 4.  Nephrology, dialysis and transplantation.

Authors:  K Farrington; P Sweny
Journal:  Postgrad Med J       Date:  1993-07       Impact factor: 2.401

Review 5.  Use of agents stimulating erythropoiesis in digestive diseases.

Authors:  Rosario Moreno López; Beatriz Sicilia Aladrén; Fernando Gomollón García
Journal:  World J Gastroenterol       Date:  2009-10-07       Impact factor: 5.742

6.  Pharmacokinetics of epoetin (recombinant human erythropoietin) after long term therapy in patients undergoing haemodialysis and haemofiltration.

Authors:  U Gladziwa; U Klotz; K Bäumer; R Zollinger; H Mann; H G Sieberth
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

7.  Pharmacokinetics of recombinant human erythropoietin applied subcutaneously to children with chronic renal failure.

Authors:  A Braun; R Ding; C Seidel; T Fies; A Kurtz; K Schärer
Journal:  Pediatr Nephrol       Date:  1993-02       Impact factor: 3.714

Review 8.  Epoetin Beta: a review of its clinical use in the treatment of anaemia in patients with cancer.

Authors:  Susan M Cheer; Antona J Wagstaff
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  Anaemia in kidney disease: harnessing hypoxia responses for therapy.

Authors:  Mark J Koury; Volker H Haase
Journal:  Nat Rev Nephrol       Date:  2015-06-09       Impact factor: 28.314

Review 10.  Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis.

Authors:  D Faulds; E M Sorkin
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.